UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 4, 2010

MEDICINOVA, INC.

(Exact name of Registrant as Specified in Its Charter)

DELAWARE	001-33185	33-0927979
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO, CA	92122
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (858) 373-1500

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Representatives of MediciNova, Inc. (the "Registrant") will be attending the CALAsia conference in San Diego, California commencing on October 4, 2010 and are scheduled to make a presentation at such conference on October 4, 2010 at 3:30 p.m. Eastern time. The information to be presented by the Registrant at the conference is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K being provided under this Item 7.01, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed "filed" for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such Section. The information in this current report on Form 8-K shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) *Exhibits*.

99.1 Slide Presentation of the Registrant.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, MediciNova has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICINOVA, INC.

Date: October 4, 2010

By: /S/ SHINTARO ASAKO
Name: **Shintaro Asako**
Title: **Vice President and Chief Financial Officer**

MEDICINOVA

Accelerating the global development and commercialization of innovative pharmaceuticals

Forward-Looking Statements

Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding MediciNova's clinical trials supporting the safety and efficacy of its product candidates and the potential novelty of such product candidates as treatments for disease, plans and objectives for clinical trials and product development, strategies, future performance, expectations, assumptions, financial condition, liquidity and capital resources. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," or similar expressions. Actual results or events may differ materially from those expressed or implied in any forward-looking statements due to various factors, including the risks and uncertainties inherent in clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities; the timing of expected filings with the FDA; MediciNova's failure to execute strategic plans or strategies successfully; MediciNova's collaborations with third parties; MediciNova's ability to realize the anticipated strategic and financial benefits from its acquisition of Avigen, Inc., to integrate the two ibudilast development programs and to pursue discussions with potential partners to secure a strategic collaboration to advance the clinical development of the combined development program; the availability of funds to complete product development plans and MediciNova's ability to raise sufficient capital when needed, or at all; intellectual property or contract rights; and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including MediciNova's annual report on Form 10-K for the year ended December 31, 2009 and its subsequent periodic reports on Forms 10-Q, 10-K and 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date September 28, 2010. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

MEDICINOVA

Corporate Overview: MediciNova, Inc.

MediciNova Overview:

- Founded in September 2000
- Headquartered in San Diego, CA
  - Additional office in Tokyo, Japan
- Dual-listing on NasdaqGM: **MNOV** and Osaka Securities Exchange as **4875**
- $63.3 million Market Cap (NasdaqGM) as of 9/28/2010

Development Company Focused on Differentiated Product Candidates

- Unique access to differentiated, potentially high-value assets primarily from Japanese alliances (Kyorin, Kissei, Mitsubishi Tanabe Pharma, Meiji)

New Approaches to Treat Serious Medical Conditions:

- MN-221: Intravenous (IV) acute asthma and COPD candidate
  - Potential $1 billion+ combined market opportunity worldwide*
- MN-166: oral multiple sclerosis, neuropathic pain, drug addiction candidate

**Source: Internal MediciNova projections*

MEDICINOVA

Business Model

In-License therapeutic small molecules from Japan to develop in US/EU for global markets



In-License:
Product candidates with significant clinical or preclinical data

Development:
Conduct Proof-of Concept (Phase I and Phase II) clinical trials

Two Pathways to ROI:

1. Continue internal development of compound towards commercialization (focus on US market)
2. Seek partnership for further development of compouds

MEDICINOVA

Why Japan?

- Recent Japanese pharma blockbusters
- Mid-size pharma firms generally must partner to reach global markets
- Opportunity for US/global developer that understands Japan
- Need for globalization by Japanese pharma as market lags behind USA and European markets



*PharmaLive Special Reports, Top 50 Pharmaceutical Companies & Their Pipelines 2010; August 1, 2010

MEDICINOVA

History:Portfolio building based on In-licensing

- Sep. 2000 Incorporated MediciNova, Inc. in San Diego, CA
- June 2001 Initiated research collaboration with Institute of Medical Sciences at University of Tokyo
- Mar. 2002 In-licensed MN-01 from Kyorin Pharmaceutical
- June 2002 In-licensed MN-02 from Angiogene Pharmaceuticals
- Feb. 2004 In-licensed MN-21 from Kissei Pharmaceutical
- Apr. 2004 In-licensed MN-35 from Mitsubishi Pharma Corp
- Oct. 2004 In-licensed MN-166 from Kyorin Pharmaceutical
- Dec. 2004 In-licensed MN-246 from Mitsubishi Pharma Corp
- Oct. 2006 In-licensed MN-447/462 from Meiji Seika Kaisha, Ltd.

Currently MediciNova has in-licensed 8 compounds

MEDICINOVA

Commercially-Attractive Diversified Portfolio

Core Candidates	Preclinical	Phase I	Phase II	Phase III
MN-166 (MS and other CNS Disorders)	Kyorin		MNOV	
MN-221(Exacerbations of Acute Asthma/COPD)	KISSEI		MNOV	
Non-Core Candidates	**Preclinical**	**Phase I**	**Phase II**	**Phase III**
MN-001 (Bronchial Asthma)	Kyorin		MNOV	
MN-305 (Anxiety Disorders)	Mitsubishi Tanabe Pharma		MNOV	
MN-001 (Interstitial Cystitis)	Kyorin		MNOV	
MN-029 (Solid Tumors)	ANGIOGENE	MNOV		
MN-221 (Preterm Labor)	KISSEI	MNOV		
MN-246 (Urinary Incontinence)	Mitsubishi Tanabe Pharma	MNOV		
MN-447/462 (Thrombosis)	Meiji			

Stage of development when licensed:

Work completed by MediciNova (MNOV) since in-license:

MEDICINOVA

Management Team with Global Experience





Leadership	Years Experience	Background
Yuichi Iwaki, MD, PhD CEO & President	34	Professor at USC, formerly Professor at University of Pittsburgh; Advisor to JAFCO, Tanabe
Shintaro Asako, CPA Chief Financial Officer	12	KPMG USA (Audit), Arthur Andersen USA
Kirk Johnson, Ph.D. Chief Scientific Officer	20	Avigen, Genesoft Pharmaceuticals, Chiron Corporation
Michael Coffee Chief Business Officer	25	Chief Business Officer, Avigen, President of Elan Pharmaceuticals, North America
Masatsune Okajima, CMA VP, Head of Japanese Office	18	Daiwa Securities SMBC, Sumitomo Capital Securities, Sumitomo Bank

MEDICINOVA

Current MediciNova Strategy

On-going Clinical Activity:

1. MN-221-CL-007 Phase II Study for Acute Exacerbations of Asthma
   - Anticipated completion 1Q, 2011*
2. MN-166 Study for Opioid Withdrawal
   - Anticipated completion in 2H, 2010*

Potential upcoming Business Deals:

1. Secure a global partnership for MN-166
2. Secure a strategic partnership for MN-221
3. Secure partnership for non-core assets to enable continued clinical development

**Anticipated completion dates based on current projections*

MEDICINOVA